Illumina, Inc. (ILMN) 2024 10-K Earnings Analysis
Illumina, Inc.2024 Earnings Analysis
71/100
For Illumina, Inc., the useful reading of FY2024 starts with scale and conversion rather than headlines: $4.37B of revenue, a net loss of $1.22B, and $709M of free cash flow. NovaSeq X Platform, GRAIL Spin-Off, and GRAIL Spin-Off Completed remain the clearest way to understand where the economics come from and why margin durability looks different here than it would at a generic peer. Gross margin of 65.4% still matters, but the better operating summary comes through NovaSeq X Platform and cash generation. The main watch item is whether the FY2024 economics prove portable into a messier environment.
Filing analysis
Illumina, Inc. 2024 10-K Analysis
This page reads Illumina, Inc.'s 2024 10-K annual report through the EarningsMoat framework: earnings quality, economic moat strength, capital allocation, and key risks. The current overall score is 71/100, or grade C.
ILMN Earnings Quality
The earnings-quality module scores 70/100, with Gross Margin: 65.4%, Net Income (One-Time): -$1.22B reported. The core question is whether reported profit is backed by operating cash flow and recurring business economics. See the earnings quality analysis guide.
ILMN Economic Moat Analysis
The moat-strength module scores 80/100, with Sequencing Standard: NovaSeq X dominance, Consumables Stream: Razor/blades. The test is whether the advantage can protect returns after competitors react. Read the economic moat analysis guide.
ILMN Free Cash Flow vs Net Income
Net Income (One-Time): -$1.22B reported, CF/Net Income (Skewed): N/M is the fastest read on whether accounting earnings turn into cash. The capital-allocation module scores 70/100. For the diagnostic, start with cash flow vs net income.
ILMN Key Risks from the Annual Report
The risk module scores 65/100, with Competitive Pressure: PacBio/Element/Ultima, Funding Cycles: Academic / pharma R&D. The goal is to separate ordinary disclosure from risks that can change margins, cash flow, leverage, or the moat itself.
Is ILMN a High Quality Earnings Stock?
Based on this 2024 filing, ILMN needs a closer read before it qualifies as a high-quality earnings candidate: the overall grade is C, and the earnings-quality score is 70/100. This is a research screen, not investment advice.
Read the report first
Understand Illumina, Inc. first, then decide if it belongs on your watchlist
The ILMN score, explanation, management facts, and filing sources are all here. When you want to follow more companies, review new-filing changes, or keep notes for the next review, keep more names in your watchlist.
Read the report first
Understand the company first. Keep up with every filing as your list grows.
A single report helps you judge one company. As your watchlist grows, review score, cash flow, moat, and risk changes together instead of repeating the same work.
Keep more names together
When your list grows, keep ILMN with the rest of your names and review score, grade, and risk changes over time.
See how to track more namesAsk follow-up questions
Dig into cash conversion, moat evidence, capital allocation, and risk changes without rereading the full 10-K.
Ask a questionExport and revisit records
Save the ILMN report as research notes you can revisit before the next filing.
Save research notesCore Dimension Scores
Evaluating competitive strength across earnings quality, moat strength, and risk sustainability
Overall Score Trend
Earnings Quality
Gross Margin is not just a statistic here; it shows that gross Margin is not just a statistic here; it shows that gross margin of 65.4% reflects the disclosed sequencing instrument and consumables product mix.
The significance of net income in FY2024 is that the significance of net income in FY2024 is that the $1.22B net loss reflects approximately $1.4B GRAIL-related impairment and disposal charges as described in the transaction footnote — underlying earnings excluding GRAIL impairment are positive per the segment-disclosure derivation.
CF / Net Income is worth reading alongside the rest of the file because CF / Net Income is worth reading alongside the rest of the file because OCF of $837M contrasts with the -$1.22B net loss — the apparent ratio is non-meaningful given the non-cash GRAIL-impairment charges. OCF is the cleaner read.
Read FY2024 in this order: $4.37B of revenue, 65.4% gross margin, $837M of operating cash flow, and then $709M of free cash flow after capex, all anchored by NovaSeq X Platform. A useful way to read the numbers is through NovaSeq X Platform and GRAIL Spin-Off, because they show where the margin discipline actually comes from. Reinvestment did not overwhelm the cash file even without a neat operating-margin shorthand. The accounting loss and the cash result diverge, so the operating engine around NovaSeq X Platform is the better reference point.
Moat Strength
Read sequencing standard as evidence that read sequencing standard as evidence that illumina's NovaSeq X (high-throughput sequencer as described in the product-launch communications) holds a leading share of the high throughput NGS market per public industry-analyst coverage.
Consumables Stream is useful mainly because consumables Stream is useful mainly because miSeq lines per the product-line disclosure) creates the captive consumables-revenue base — the razor and blades economics.
Goodwill / Assets matters because goodwill / Assets matters because goodwill of $1.12B on $6.30B assets equals 17.7% per the FY2024 balance sheet — modest after the substantial GRAIL acquired goodwill writedown as described in the impairment footnote.
NovaSeq X Platform and GRAIL Spin-Off are the most concrete evidence that this business is harder to dislodge than the average peer. GRAIL Spin-Off Completed and Francis keep the economics sticky by giving customers more reasons to stay inside the same ecosystem. ROE at -51.5% is not the reason the moat exists, but it does show that NovaSeq X Platform is still surfacing in returns. The company can still be challenged, yet the challenger has to do more than offer a cheaper substitute where NovaSeq X Platform already sits in the workflow.
Capital Allocation
Free Cash Flow matters in capital allocation because free Cash Flow matters in capital allocation because FCF of $709M (OCF $837M minus capex $128M) demonstrates underlying cash generation despite the GAAP loss.
The allocation takeaway from grail spin-off completed is that the allocation takeaway from grail spin-off completed is that FTC challenge as described in the regulatory-action communications) — but at substantial impairment cost per the FY2024 transaction footnote.
Capital Discipline is relevant because capital Discipline is relevant because illumina is refocusing on core sequencing business discipline as described in the strategic-priority communications.
FY2024 left management with $709M of free cash flow after reinvestment, so the discussion around NovaSeq X Platform is about choice rather than survival. A light reinvestment burden of 2.9% of revenue means optionality around NovaSeq X Platform comes from choice, not from forced austerity. Liquidity looks adequate with $1.13B of cash, so leverage is not the first thing to focus on. This capital-allocation file is still tilted toward internal use of cash rather than toward an aggressive payout posture.
Key Risks
Competitive Pressure is worth tracking because competitive Pressure is worth tracking because ultima Genomics per public industry communications) and long-read incumbent (PacBio as described in the competitor list) challenge Illumina's installed-base economics.
The risk significance of funding cycles is that the risk significance of funding cycles is that illumina's instrument and consumables revenue depends on academic-research and pharma-R&D funding cycles as described in the customer-base communications.
Strategy Execution belongs on the watch list because strategy Execution belongs on the watch list because post-GRAIL strategic-execution credibility depends on demonstrated cost-discipline and sequencer installed base monetization as described in the strategic-priority communications.
Investors do not need one dramatic risk to worry about; the harder problem is the mix of execution pressure and operating pressure. The reason to watch the risk file closely is that execution pressure can deteriorate the economics through several small channels at once. Portfolio execution still matters because goodwill represents 17.7% of assets and leaves less room for poor follow-through around NovaSeq X Platform. The main watch item is whether the FY2024 economics prove portable into a messier environment.
Management
Ask about this section
Ask one question here. Keep digging when the issue needs more work.
This analysis is for educational purposes only and does not constitute investment advice.